76th Session of the WHO Regional Committee for the Western Pacific on “Implementing the International Health Regulations (2005) amendments”
On 21 October 2025 in Nadi, Fiji, IFPMA delivered a statement at the 76th Session of the WHO Regional Committee for the Western Pacific on “Implementing the International Health Regulations (2005) amendments.”
We commend the Western Pacific Region for its engagement to develop priority actions for countries and areas in the region to utilize the amended International Health Regulations (IHR) to strengthen regional operational readiness for public health emergencies and promote resilience, equity, and solidarity.
As the implementation of the IHR (2005) amendments moves forward, and preparations for the WHO Pandemic Agreement continue, it is essential to maintain a coherent and inclusive approach. In particular, we emphasize the importance of allowing the Intergovernmental Negotiating Body (INB) and the Intergovernmental Working Group (IGWG) to complete their work—especially on the Pathogen Access and Benefit-Sharing (PABS) annex—before introducing new actions.
Multi-stakeholder engagement at the regional level will be critical to ensure that future frameworks are practical, innovation-friendly, and aligned with the realities of public health response. The innovative pharmaceutical industry stands ready to contribute its expertise and we encourage continued dialogue and collaboration to ensure that the Western Pacific Region remains a model for inclusive, forward-looking pandemic preparedness and response.
About IFPMA
IFPMA represents the innovative pharmaceutical industry at the international level, engaging in official relations with the United Nations and multilateral organizations. Our vision is to ensure that scientific progress translates into the next generation of medicines and vaccines that deliver a healthier future for people everywhere.
ifpma.org
To achieve this, we act as a trusted partner, bringing our members' expertise to champion pharmaceutical innovation, drive policy that supports the research, development, and delivery of health technologies, and create sustainable solutions that advance global health.
Related news and resources
Statement on PABS system at the second meeting of the open-ended Intergovernmental Working Group (IGWG 2) on the WHO Pandemic Agreement
On 15 September 2025 in Geneva, IFPMA delivered a statement at at the second meeting of the open-ended Intergovernmental Working Group (IGWG 2) on the WHO Pandemic Agreement.
Read moreOpen letter from the innovative pharmaceutical industry to G7 leaders
Ahead of the G7 Leaders’ Summit in Kananaskis from 15 to 17 2025, the global pharmaceutical industry, represented by the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) and Innovative Medicines Canada (IMC), are calling on G7 governments to place health and innovation at the top of their agenda.
Read morePharmaceutical industry calls on G7 to prioritize innovation as strategic pillar for health, growth, and security
Ahead of the G7 Leaders’ Summit, IFPMA and Innovative Medicines Canada (IMC) reaffirm the innovative pharmaceutical industry’s commitment to partnering with G7 governments to improve patient outcomes, strengthen health systems, boost economic growth, and support national security.
Read more